

One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa / CD16a structure

Reviewed Preprint

v2 • October 15, 2024

Revised by authors

Reviewed Preprint

v1 • August 21, 2024

Paul G Kremer, Elizabeth A Lampros, Allison M Blocker, Adam W Barb 

Department of Biochemistry and Molecular Biology, University of Georgia, Athens, United States • Complex Carbohydrate Research Center, University of Georgia, Athens, United States • Department of Chemistry, University of Georgia, Athens, United States

 https://en.wikipedia.org/wiki/Open_access
 Copyright information

Abstract

Both endogenous antibodies and a subset of antibody therapeutics engage Fc gamma receptor (Fc γ R)IIIa / CD16a to stimulate a protective immune response. Increasing the Fc γ RIIIa/IgG1 interaction improves the immune response and thus represents a strategy to improve therapeutic efficacy. Fc γ RIIIa is a heavily glycosylated receptor and glycan composition affects antibody-binding affinity. Though our laboratory previously demonstrated that natural killer (NK) cell N-glycan composition affected the potency of one key protective mechanism, antibody-dependent cell-mediated cytotoxicity (ADCC), it was unclear if this effect was due to Fc γ RIIIa glycosylation. Furthermore, the structural mechanism linking glycan composition to affinity and cellular activation remained undescribed. To define the role of individual amino acid and N-glycan residues we measured affinity using multiple Fc γ RIIIa glycoforms. We observed stepwise affinity increases with each glycan truncation step with the most severely truncated glycoform displaying the highest affinity. Removing the N162 glycan demonstrated its predominant role in regulating antibody-binding affinity, in contrast to four other Fc γ RIIIa N-glycans. We next evaluated the impact of the N162 glycan on NK cell ADCC. NK cells expressing the Fc γ RIIIa V158 allotype exhibited increased ADCC following kifunensine treatment to limit N-glycan processing. Notably, an increase was not observed with cells expressing the Fc γ RIIIa V158 S164A variant that lacks N162 glycosylation, indicating the N162 glycan is required for increased NK cell ADCC. To gain structural insight into the mechanisms of N162 regulation, we applied a novel protein isotope labeling approach in combination with solution NMR spectroscopy. FG loop residues proximal to the N162 glycosylation site showed large chemical shift perturbations following glycan truncation. These data support a model for the regulation of Fc γ RIIIa affinity and NK cell ADCC whereby composition of the N162 glycan stabilizes the FG loop and thus the antibody-binding site.

eLife Assessment

This study explores the mechanistic link between glycosylation at the N162 site of the Fc gamma receptor FcγRIIIa and the modulation of NK cell-mediated antibody-dependent cytotoxicity. Using innovative isotope labeling strategies and advanced NMR spectroscopy techniques, the authors provide **compelling** evidence of how glycan composition influences receptor stability and immune function. These findings offer **fundamental** insights that may contribute to the development of more effective therapeutic antibodies. The manuscript will be of significant interest to immunologists and researchers focused on therapeutic antibody design.

<https://doi.org/10.7554/eLife.100083.2.sa3>

Introduction

Natural killer (NK) cells rapidly respond to destroy tissue coated with antibodies. This protective mechanism, termed antibody-dependent cell-mediated cytotoxicity (ADCC), is likewise exploited by many therapeutic monoclonal antibodies (mAbs) recognizing specific epitopes that escape detection by endogenous antibodies. However, NK cell ADCC elicited both by endogenous antibodies and mAbs fails to ameliorate disease in many patients. There is sufficient evidence to expect that increased NK cell ADCC will improve patient responses though few strategies exist to achieve this outcome.

NK cells require binding of antibodies to only a single receptor type, Fc gamma receptor IIIa (FcγRIIIa/CD16a), to elicit ADCC. Multiple lines of evidence support the role of increased antibody-binding affinity in improved NK cell responses. NK cells expressing the higher affinity FcγRIIIa V158 allotype demonstrate greater ADCC than those expressing the weaker-binding F158 allotype (hereafter referred to as V158F) [1–4]. Furthermore, improving the FcγRIIIa-binding affinity of antibodies, which bind through the Fc region, likewise increases ADCC and therapeutic potency [5–7]. Antibody engineering efforts have been widely explored to improve ADCC by increasing FcγRIIIa engagement, however, substantially less is known about structural mechanisms that affect FcγRIIIa function.

Our laboratory identified an unexpected strategy to increase FcγRIIIa affinity. We determined that FcγRIIIa glycosylation affected antibody-binding affinity, with oligomannose-type N-glycans providing higher affinity interactions [8,9]. Oligomannose N-glycans are minimally-remodeled forms that are not expected at high percentages on secreted proteins in contrast to highly remodeled complex-type glycans found on most serum glycoproteins [10]. Among the five FcγRIIIa N-glycosylation sites, the composition of the glycan at N162 is responsible for increased antibody-binding affinity and is located near the interface formed with the antibody Fc [9,11]. Furthermore, we identified a high degree of glycan compositional heterogeneity at the N162 site on FcγRIIIa purified from NK cells of healthy human donors including both complex-type and oligomannose glycoforms [12–14]. YTS cells, a key cytotoxic human NK cell line used for these studies, express FcγRIIIa with extensive glycan processing, including the N162 site with predominantly hybrid and complex-type glycoforms [15]. The N162 glycan heterogeneity on NK cells is reflected in the presence of both high-affinity and low-affinity FcγRIIIa forms in the periphery of healthy donors, with high affinity forms more abundant in adult donors compared to children [16].

We likewise demonstrated that NK cell N-glycan processing reduced ADCC potency. NK cells with limited N-glycan remodeling capability, following either treatment with kifunensine or knockdown of the bottleneck glycan processing enzyme MGAT1, demonstrated increased ADCC [16, 17]. These studies, however, did not determine that FcγRIIIa N-glycan processing, nor the composition of the N162 glycan, mediated the increased ADCC. It is equally possible that this role is mediated by other NK cell glycans, of which hundreds are expected. Demonstration of the role of the N162 glycan in ADCC is expected to promote improved ADCC responses through efforts to tune glycan composition of endogenous NK cells or infused NK cells. Furthermore, such a demonstration is expected to promote FcγRIIIa engineering to increase ADCC beyond levels available from endogenous NK cells and naturally-occurring FcγRIIIa variants.

Here we investigate the N162 glycan's role in FcγRIIIa structure, antibody-binding affinity and NK cell ADCC. We performed a mutational screen to identify FcγRIIIa residues that mediate antibody binding affinity and sensitivity to the N-glycan composition. Introducing a subset of these FcγRIIIa variants, displaying a range of affinities, into cytotoxic NK cells provided insight into the relationship between antibody-binding affinity and ADCC. We then defined the impact of N162 glycan composition on NK cell ADCC and FcγRIIIa structure. As a result, we define a link between the N162 glycan composition and NK cell ADCC.

Results

FcγRIIIa affinity impacts ADCC

We generated a library of FcγRIIIa proteins with mutations at the antibody-binding interface to identify key residues. The resulting FcγRIIIa proteins revealed a wide range of affinities between those slightly higher than wild type (S164A) to a handful with no apparent binding at 2.5 μM to fucosylated IgG1 Fc (Y132S, W90A, W113A; **Figure 1A**, **Table S1**). Mapping the impact of these mutations onto a FcγRIIIa structural model identified two key regions consistent with empirically-derived structural models of the antibody:receptor complex [11], though our data provide greater detail showing how each residue affects affinity. These two regions center around Y132 and a pair of tryptophan residues (W90 and W113) which overlaps with the contact interface identified by X-ray crystallography (**Figure 1B**). Surprisingly, although the K161A mutation reduces affinity by 10-fold, mutating adjacent residues including S160 showed little direct impact on affinity. It was likewise surprising that the solvent-exposed, large hydrophobic side chains of F153 and I88 minimally impacted affinity (<2 fold). A majority of the mutations only impacted affinity by 3-fold or less.

The FcγRIIIa V158 allotype (hereafter referred to as the wildtype) binds ~4-fold tighter than the more common V158F allotype and NK cells expressing the wildtype likewise exhibit greater ADCC [1, 18], however, beyond these two points the relationship between FcγRIIIa affinity and ADCC remains undefined [19]. A positive correlation between affinity and ADCC would indicate improved NK-cell mediated therapies may result from increasing the FcγRIIIa antibody-binding affinity beyond that of the wild type. This FcγRIIIa library evaluated above, plus a range of other mutations proximal to this interface, provides a wide range of FcγRIIIa affinities (the complete binding affinities of all FcγRIIIa variants are shown in Supplemental Table 1).

We next evaluated the impact of FcγRIIIa mutations on ADCC potency. We transduced cytotoxic YTS NK cells to express a subset of FcγRIIIa variants from our affinity screen, encompassing a broad affinity range, using lentivirus to establish stable cytotoxic NK cell lines. Each YTS cell line displayed comparable FcγRIIIa expression, however at levels somewhat reduced from the original YTS-FcγRIIIa cell line provided by Dr. Mace (Columbia U., **Figure S1**). A comparison of the original YTS-FcγRIIIa (V158) cells and our transduced YTS cell line expressing the same wildtype receptor showed greater expression and greater ADCC from the original YTS-FcγRIIIa cell line




Figure 1.

FcγRIIIa antibody-binding affinities correlate with ADCC potency.

A. Affinities of FcγRIIIa amino acid variants determined by SPR are binned into impact: 2-fold lower (*light blue*), between 2 and 4-fold (*blue*), or greater than 4-fold lower than V158 (*dark blue*). **B.** Plotting these values onto a surface representation of FcγRIIIa, using the same coloring scheme as in A., reveals two critical areas for binding centered around W113 and Y132 (top panel). These values provide more detail in contrast to the interface defined by X-ray crystallography with contacts shown <3 Å (*black surface*) and <5 Å (*grey surface*). **C.** ADCC of YTS cells transduced to express a panel of FcγRIIIa variants. Horizontal black bars represent average ADCC values, with individual point representing individual assays. Experiments were completed in triplicate and the figure includes data from multiple experiments collected on multiple days. **D.** A comparison of ADCC values from panel C and binding affinity from panel A shows a correlation.

likely resulting from our cell isolation strategy that selected only for GFP⁺ cells rather than FcγRIIIa expression. Within our library, YTS cells expressing the FcγRIIIa S164A variant displayed the highest average ADCC and the tryptophan mutants showed no detectable ADCC, indicating higher affinity leads to higher ADCC (**Figure 1C**). A plot of the affinity for each variant versus the ADCC potency demonstrated a trend linking high affinity and greater ADCC. These results indicate that greater FcγRIIIa antibody-binding affinity on NK cells increases ADCC and FcγRIIIa engineering represents an unexplored avenue to improve NK cell-mediated immunotherapies.

The FcγRIIIa N162-glycan is required for high affinity interactions with afucosylated IgG

Because affinity is a key determinant of ADCC potency, we further explored FcγRIIIa changes that affect affinity and to identify variants with altered sensitivity to IgG1 Fc glycan composition. Shields et al. previously showed that antibody fucosylation reduces affinity for FcγRIIIa [20] and it is known that the N162 glycan mediates the response to fucose, though the underlying mechanism remains disputed [21–24]. We identified FcγRIIIa residues within the contact distance of the N162 glycan to explore the impact of proximal residues to antibody fucosylation. We next evaluated mutations at each contact site using both the wild type and S164A variant that prevents N162 glycosylation. These variants largely exhibited decreased affinity compared with the wild type FcγRIIIa when evaluated against fucosylated IgG1 Fc (**Figure 2A**). Surprisingly, each variant displayed reduced sensitivity to fucose when the N162 glycan was absent. The impact of fucose reduced from a 2.2-fold average effect when the N162 glycan was present to a 1.3-fold change when the N162 glycan was absent (**Figure 2B**). Most variants bound afucosylated IgG1 Fc with weaker affinity. The F153S and R155S variants lacking the N162 glycan are notable outliers in that both bind antibody glycoforms with higher affinity than the wild type. These data also are consistent with the hypothesis that intermolecular glycan-glycan contacts provide minimal stability to the antibody/receptor complex because higher affinity was achieved by removing the N162 glycan.

N-glycan truncations reveal how each residue contributes to affinity

In addition to glycan composition of the IgG1 Fc ligand affecting affinity, composition of the FcγRIIIa glycans likewise impacts antibody-binding affinity [8,9]. It is tempting to conclude from the preceding study that higher affinity interactions can be achieved through removing the N162 glycan entirely, however, our previous work showed that truncating the glycan to a single (1)GlcNAc residue provides superior affinity though it was unclear if these changes mapped to the N162 site [19]. It is also possible that glycoforms slightly longer than the (1)GlcNAc truncated form provide even greater affinity though this possibility remained untested. To identify which N-glycan residues affected affinity, we treated recombinant FcγRIIIa with a series of glycosidases to sequentially remove terminal sugars from the non-reducing end (**Figure S2**). We observed a step-wise increase in affinity following the removal of each type of terminal sugar (**Figure 2C**, left panel). Removing the core α-linked mannose or sialic acid residues showed the greatest change for a single removal step, increasing affinity by 5-fold or 2-fold respectively. Overall, glycan truncation was observed to decrease K_D by 12-fold. To evaluate the individual impact of the N162 glycan, we next truncated glycans of the S164A variant that lacks N162 glycosylation but retains four other N-glycans (**Figure 2B**, right panel). While the S164A affinities followed the same trend as the wild type, the changes were substantially smaller in magnitude with only a 4-fold overall change. The removal of the core α-linked mannose residues increased affinity by less than 1.5-fold, in contrast to the 5-fold increase observed for the wild type. These results demonstrate the primary contribution of the N162 glycan composition to antibody-binding affinity, with smaller




Figure 2.

The FcγRIIIa N162 glycan regulates affinity towards fucosylated and afucosylated IgG1 Fc.

A. FcγRIIIa variants demonstrate higher affinity towards without IgG1 Fc core-fucosylation (*open circles*) than with this modification (*red circles*). The affinity increase is demarcated with a vertical arrow. When the N162 glycan was removed through the S164A mutation, the fucose sensitivity greatly diminished. **B.** Comparison of the fold affinity increase in panel A. due to removing IgG1 Fc fucose. Averages for the fold increase with the N162 glycan present and absent are noted on the x and y axes, respectively. **C.** The affinities of six different FcγRIIIa glycoforms were measured with and without the N162 glycan (wt and S164A, respectively). Horizontal black bars represent the means and individual measurements are shown with closed *black circles*. Cartoon models utilize the SNFG nomenclature and represent the possible N-glycan compositions for each species.

contributions from N-glycans at the remaining four sites. Furthermore, these data demonstrate the negative impact of adding additional residues throughout the processing pathway, further indicating that N-glycan processing inhibits antibody-binding affinity.

The FcγRIIIa N162 glycan is required for increased ADCC potency following kifunensine treatment

The data above demonstrate the impact of FcγRIIIa N162 glycan composition on antibody-binding affinity. Furthermore, our lab previously showed that inhibiting NK cell glycan processing, and thus FcγRIIIa processing, increased ADCC potency [16, 17]. However, these studies did not determine that composition of the FcγRIIIa N162 glycan affected ADCC potency. We expect that the FcγRIIIa N162 glycan composition that was shown to mediate high affinity interactions with IgG1 Fc likewise is required for the potent ADCC observed following blockage of NK cell N-glycan processing [9, 17]. To evaluate the role of N162 glycosylation in NK cell ADCC, we treated our FcγRIIIa-expressing YTS NK cell lines from **Figure 1C** with kifunensine, an inhibitor of N-glycan processing that specifically reduced YTS cell N-glycan processing [16]. As expected based on our lab's previous work, the YTS cells expressing the FcγRIIIa wild type demonstrated increased ADCC following kifunensine treatment (**Figure 3**). Cells expressing the V158F variant likewise demonstrated a 1.4-fold ADCC increase following kifunensine treatment. We observed a similar result for YTS cells expressing the T167Y variant. However, YTS FcγRIIIa cells lacking only the N162 glycan through the S164A mutation demonstrated no increase following kifunensine treatment. Notably, the wild type, V158F and T167Y variants all contain the N162 glycan but only S164A does not, thus, the N162 glycan is required for increased ADCC potency following kifunensine treatment.

We next evaluated afucosylated antibodies in combination with kifunensine in our cell lines, having previously demonstrated afucosylated antibodies acted synergistically with kifunensine treatment to increase NK cell ADCC [17]. The YTS cells expressing wild type FcγRIIIa evaluated with afucosylated antibody showed a significant increase following kifunensine treatment compared to those evaluated with the fucosylated antibody (**Figure 3**). Notably, we observed no further benefit for the S164A variant with afucosylated antibodies. This result indicates that the N162 glycan is a critical mediator of increased ADCC responses following inhibiting both NK cell glycan remodeling and antibody fucosylation.

FcγRIIIa backbone resonance assignment

Having demonstrated the role for the FcγRIIIa N162 glycan in antibody binding affinity and NK cell ADCC, we next evaluated how glycan composition affects FcγRIIIa structure to identify regions of the protein that modulate affinity. We probed the effect of N-glycan composition using solution NMR spectroscopy, a technique that evaluates FcγRIIIa structure in dilute solutions and can identify the impact of highly mobile elements including disordered loops, N and C termini, and glycans. First, individual peaks in the NMR spectra must be assigned to unique atoms in the protein to evaluate structural changes with atomic resolution. N-glycoproteins, including FcγRIIIa, represent a significant challenge for NMR spectroscopy due to exceptional line broadening and thus signal loss resulting from the presence of extended N-glycans that slow molecular tumbling. As a result of these physical limitations, N-glycoproteins are seldom investigated by NMR despite their prevalence in the human proteome (22% of the human proteome enters the secretory pathway and contains an N-glycosylation site). Broad spectral lines dramatically limit the quality of multi-dimensional spectra required for the standard resonance assignment strategies, preventing the collection of CB frequencies that provide a high degree of amino acid discrimination.

To surmount these limitations, we first increased tumbling and thus spectral quality by mutating three of the five N-glycosylation sites, retaining N-glycans at N45 and N162 that stabilize antibody binding and solubility [9]. The spectrum of the FcγRIIIa N38Q/N74Q/N169Q variant with two N-




Figure 3.

The FcγRIIIa N162 glycan regulates NK cell ADCC.

The ADCC of NK cells increases significantly following 20 μ M kifunensine for YTS cells expressing FcγRIIIa that retains the N162 glycan (wild type, V158F, T167Y). Removing the N162 glycan with the S164A mutation eliminates this increase. In addition to kifunensine, these cells demonstrate significant ADCC increases from afucosylated rituximab (RTX) compared to fucosylated RTX. The YTS cells FcγRIIIa S164A cells likewise demonstrate no increased ADCC following kifunensine treatment when using afucosylated RTX, unlike YTS cells expressing the wild-type FcγRIIIa. Observations made using an afucosylated antibody are shown in *red*. Data shown include three independent experiments collected on three different days, each with three replicates. P-values from two-tailed t-tests are shown at the top. Raw ADCC values supporting this figure are presented in Supplemental Figure 2.

glycans improved and peak positions proved highly comparable to those from FcγRIIIa with five N-glycans. Next, we simplified the assignment problem by defining the amino acid type for many peaks in the spectrum through specific amino acid labeling. Our strategy supplements the HEK293F growth medium with individual [¹⁵N]-labeled amino acids [25], and provided residue information for 13 types (C,F,G,H,I,K,N,R,S,T,V,W,Y; an example spectrum is shown in **Figure S3**). These residue-type assignments guided the definition of residue connections, and thus the backbone assignment, in three-dimensional HNCA and HN(CO)CA spectra. Carbonyl carbon resonances were then assigned using an HNCB experiment. As a result, we assigned a high percentage of the backbone resonances (87% N, 90% HN, 86% CO, 86% CA) and almost all the peaks in the 2d HSQC-TROSY spectrum (**Figure 4AB**). This resonance assignment is suitable for interpreting structural changes associated with changing the N-glycan composition and represents a significant triumph due to the challenges associated with glycoprotein NMR. To our knowledge, this is the only NMR resonance assignment of a glycoprotein with two N-glycans attached. A small handful of assignments exist for proteins with one N-glycan, notably CD2 and the Fc region of IgG1 (a thermostable dimer) [26,27].

A comparison of the peak positions between the FcγRIIIa assignment and a previous assignment of the similar FcγRIIIb protein reveals a high degree of overlap but a few notable differences (**Figure 4C**). These two proteins differ by eight amino acids, though FcγRIIIb was expressed in *E. coli* and thus is not glycosylated [28]. Two notable differences occur at C71 and C110 that are distinguished in the HNCA and HN(CO)CA spectra support this assignment (**Figure S4**). Surprisingly, the N-glycosylation of the N45 and N162 residues revealed minimal impact on the backbone peak positions for these asparagine residues. A few other differences emerged in regions near amino acid differences, notably position 18 and the contact region of ~80-99, as well as 38, 129 140 and 169. We previously defined local structural differences resulting from substitution at position 129 using X-ray crystallography that are consistent with this NMR-based analysis [29].

FcγRIIIa N-glycan composition affects the structure of the antibody-binding site

We applied our protein labeling approach and backbone resonance assignment to define individual FcγRIIIa atoms that experience different environments based on N-glycan composition. We expressed three FcγRIIIa glycoforms with six [¹⁵N]-labeled amino acids to introduce probes throughout the polypeptide (**Figure 5A**, **Figure S5**). The spectra showed dispersed peaks that revealed differences between different glycoforms (**Figure 5C**). A few residues showed evidence for the sampling of multiple conformations, notably V158 and K161. These residues are located on the FG loop that contains the N162 glycan. The peaks simplify as the glycan becomes shorter, up to the point of a single peak observed for V158 with the (1)GlcNAc glycoform that may indicate either sampling of a single conformation or more rapid exchange between two or more conformations.

Mapping the chemical shift perturbations to the primary sequence revealed residues proximal to the five N-glycosylation sites when comparing the receptor with complex-type glycans to that with Man5 N-glycans (**Figure 5DE**). Truncation to the (1)GlcNAc glycoform caused greater changes to the regions around the N45 and N162 glycans (**Figure 5DF**). These data likely indicate a change in the FcγRIIIa conformation sampled by residues near the FG loop, and potentially changes in the orientation between the two extracellular domains as chemical shift differences likewise map to regions near the connection between these two domains. Features associated with the (1)GlcNAc spectra represent conformations that promote higher affinity interactions, as this glycoform binds antibody with the greatest affinity of those evaluated. We anticipate that these conformations are sampled by these residues on the surface of natural killer cells, and the conformational sampling on the cell surface is dictated by the N162 glycan composition.




Figure 4.

Backbone resonance assignment of FcγRIIIa with N-glycans at N45 and N162.

Amino acid position within the sequence of 175 residues and the residue type are shown. **A.** the entire ^1H - ^{15}N HSQC-TROSY spectrum. **B.** expansion and additional assignments within the inset. **C.** A comparison of the assigned ^1H and ^{15}N resonances from the glycosylated FcγRIIIa to FcγRIIIb expressed from *E. coli* that contains no N-glycans. Sequence differences are noted in the figure, with the bottom letter denoting the FcγRIIIa residue. N* = a glycosylated asparagine residue.




Figure 5.

Glycan composition changes the FcγRIIIa backbone conformation.

A. Diagram of the protein expression, labeling and glycan remodeling procedures. **B.** Example HSQC-TROSY spectrum of FcγRIIIa with the truncated (1)GlcNAc N-glycan labeled with ¹⁵N-(Val,Leu,Ile) during expression. **C.** Isolated peaks show differences in position between different glycoforms. **D.** The observed Chemical Shift Perturbation (CSP) between complex-type and Man5 N-glycans (blue) or Man5 and (1)GlcNAc N-glycans (red) is shown by residue number. **D.E.** CSP's >0.03 (light) and >0.06 (dark) mapped to a ribbon model of FcγRIIIa. Truncation to (1)GlcNAc causes CSPs near the Fc-binding interface that is proximal to N162.

Evidence supporting distinct conformations of the FcγRIIIa FG loop

Solution NMR evidence identified differential FcγRIIIa conformational sampling, particularly residues in the FG loop, and is supported by the appearance of distinct conformations identified by X-ray crystallography. A recent structure isolated one conformation of the FG loop that differed from those previously observed, mostly through structures bound to IgG1 Fc [11,24,30]. In this recent structure of glycosylated FcγRIIIa, the FG loop is free from contacts with the Fc ligand or with the crystal lattice, revealing a conformation that is sterically prohibited in the complex with antibody (Figure 6A). To bind, the N162 glycan and the FG loop must reorient to avoid steric clashes with IgG1 Fc. The backbone conformation of the supporting beta strands shows minimal displacement, though larger backbone deviations are observed for the L157, K161 and S164 residues (Figure S6). The presence of these distinct conformations is supported by the NMR spectra showing two peaks, including V158 and K161 (Figure 5C). We investigated conformational sampling further with 1 μs all-atom MD simulations and found the presence of both conformations identified by X-ray crystallography in trajectories of FcγRIIIa with complex-type or Man5 N-glycans (Figure 6B). These simulations were initialized with a starting structure representing the bound state-conformation but sampled both conformations throughout the experiment. One notable detail from these simulations was the formation of non-covalent interactions between the aliphatic portion of the R155 sidechain with the hydrophobic surface of the (1)GlcNAc residue in the ligand-bound conformation that were absent in the unliganded conformation. To evaluate the importance of this interaction, we measured the binding affinity of the truncated FcγRIIIa (1)GlcNAc glycoform lacking the R155 sidechain. The FcγRIIIa R155S (1)GlcNAc glycoform bound IgG1 Fc with a 5-fold weaker affinity compared to the wild type in the same glycoform (Figure 6C, Table S1). The R155S binding is comparable to the S164A mutant lacking the N162-glycan, and mutation of a nearby residue retaining the N-glycan F153S retains the benefit of the (1)GlcNAc/R155 interaction. These data demonstrate a role for the R155 sidechain to stabilize the binding-competent conformation.

Discussion

The N162 glycan regulates NK cell ADCC

Removing the N162 glycan eliminated the ADCC gains following inhibiting NK cell N-glycan processing with kifunensine, demonstrating a unique role for this protein modification in the immune system. These data demonstrate why NK cell ADCC is sensitive to changes of the N-glycan composition, an effect that was previously shown to require antibody binding to FcγRIIIa [17]. This result is likewise consistent with prior binding affinity measurements defining a role for N162 glycan composition as a factor in antibody-binding affinity [8,9]. The binding affinity differences due to glycan composition are supported through studies of both human FcγRIIIa and macaque FcγRIII [2,31,32]. The simple observation that the N162 glycan alone accounts for the sensitivity of differences in NK cell ADCC due to N-glycan processing is belied by the potentially enormous number of alternative hypotheses that ADCC is influenced by any other N-glycan on the NK cell surface. However, a distinction can be made between these explanations because of the simple difference of a single S164A mutation that eliminated the N162 glycosylation site. The specificity of this result defines a role for N162 glycan composition in NK cell ADCC.

We propose that the N162 glycan regulates NK cell ADCC, representing a previously undescribed regulatory element. The appearance of endogenous heterogeneity of the N162-glycan supports the assertion. The N162 glycan composition isolated from peripheral NK cells is notably heterogeneous, in contrast to the four remaining FcγRIIIa N-glycans that show remarkable similarity between different donors and cell types [12–14]. Thus, the FcγRIIIa N162 glycan composition is variable on endogenous NK cells, likely providing a range of ADCC potency. It remains unclear how cells produce variability restricted to the N162 N-glycan, with a high degree




Figure 6.

Binding antibody induces an FcγRIIIa conformational change.

A. Two conformations of the FG loop previously captured by X-ray crystallography (pdb 7seg, 5vu0). Both the FG loop and the N-glycan become restricted to accommodate IgG1 Fc. The conformational entropy of a complex-type N-glycan, with more rotatable bonds, is greater as is the loss of entropy upon binding compared to smaller N-glycans. **B.** Binding affinity of FcγRIIIa variants following EndoF1 digestion, displaying a truncated (1)GlcNAc N-glycan. **C.** Evidence for conformational sampling in the unliganded FcγRIIIa revealed by all-atom molecular dynamics simulations. Each data set show the average of two independent 1 μ s trajectories, with separate experiments for FcγRIIIa with Man5 N-glycans or complex-type N-glycans.

of similarity at the remaining four sites on the same protein despite the physical linkage that exposes these glycans to comparable conditions during secretion. Identifying this mechanism that affects N162 glycan processing has the potential to impact cellular immunotherapies if endogenous processing can be tuned *in vivo*. Furthermore, the advent of infused NK cell-based therapies provides a mechanism to deploy FcγRIIIa engineered with greater affinity or altered sensitivity to glycan composition of the expressing cell of the antibody ligand [33]. Removing the N162 glycan with the S164A mutation removes variability related to NK cell glycan processing, a potential confounding but unexplored factor in NK cell culture. Removing this glycan likewise reduces the impact of afucosylated antibodies on ADCC, which may be preferable if pathogenic afucosylated antibodies are present or enhanced ADCC is not desirable. Afucosylated antibodies have been reported at high titers during various autoimmune or viral diseases [34–36].

Relationship between FcγRIIIa affinity and ADCC

Multiple lines of evidence indicate ADCC responses improve with antibodies engineered to engage FcγRIIIa with improved affinity, however, much less information is available for how improved the FcγRIIIa antibody-binding affinity affects ADCC. This information is important to predict how future affinity improvements will impact ADCC. It is not obvious that increased antibody-binding affinity would promote greater ADCC considering the highly multivalent nature of the NK cell interaction with an opsonized target cell. Here we quantified ADCC using NK cells expressing a range of FcγRIIIa affinities outside the range defined by the natural V158 and V158F allotypes. Affinities lower than 300 nM showed little, if any, ADCC. Though donor NK cells displaying the V158F allotype exhibit measurable ADCC [37], our reduced ADCC is likely due to the lowered FcγRIIIa expression, as noted in **Figure S1**. Affinities greater than 300 nM showed substantial cytotoxicity with a sharp increase at greater affinities indicating that greater FcγRIIIa antibody-binding affinity is expected to further increase ADCC. Notably, the ADCC potency for those high-affinity variants does not fall cleanly on a line, indicating that other factors affect our observations, which may include organization at the cell surface, changes to glycan composition, or receptor trafficking. Thus, these data define a positive relationship between FcγRIIIa affinity and ADCC.

A structural mechanism linking N162 composition to increased affinity

Analysis of unliganded and Fc-bound FcγRIIIa reveals structural differences proximal to N162 that are supported by the appearance of multiple conformations in NMR spectra and MD simulations. Both the FG loop and its attached N162 glycan move from a position in the unliganded state that allows maximum flexibility to a restricted state to accommodate Fc binding (**Figure 6A**). Furthermore, the sequential truncation of glycan residues provides increasingly greater affinity that is due largely to the N162 glycan (**Figure 2C**). We believe this result is best explained by a conformational entropy penalty introduced upon complex formation by shifting the N162 glycan to a restricted space between surfaces formed by the Fc and FcγRIIIa polypeptide. An alternative hypothesis, analogous to IgG1 Fc with intramolecular interactions stabilizing the N-glycan to increase affinity, appears to be less suitable for the FcγRIIIa data presented here largely because FcγRIIIa affinity increases following glycan truncation unlike IgG1 Fc N-glycan truncation that decrease affinity [38,39]. Indeed, previous MD simulations likewise demonstrated a loss of N162 glycan conformational heterogeneity upon binding [24].

A loss of N162 glycan conformational entropy alone is sufficient to explain the observed 1.7 – 2.2 kcal mol⁻¹ difference in binding affinities [9]. A simple calculation, assuming three equally populated conformations in the unliganded state per rotatable bond, provides an estimate of the difference between the change of conformational entropy upon binding for the complex-type and Man5 N-glycans of 4.8 kcal mol⁻¹ [40]. This value likely overestimates the penalty, being based on sampling only one N-glycan conformation in the Fc-bound state and notably excludes solvent entropy. Prior ITC analyses of these interactions revealed enthalpy/entropy compensation that

precluded a clear definition of the contribution from conformational entropy from those data alone [24]. The entropic penalty is likely also alleviated by stabilizing interactions between the (1)GlcNAc residue and the R155 sidechain, explaining why the truncated glycoform displays a greater affinity than the S164A variant that lacks the N162 glycan.

FcγRIIIa hotspots at the antibody-binding interface

Though high resolution structural models for the antibody binding interface are available, the impact of individual residues on binding affinities are not always trivial to predict and thus it is often unclear which residue to target in protein engineering efforts to tune affinity. Our FcγRIIIa mutant screen mapped important residues involved in antibody binding as shown in **Figure 1** to complement one prior study of G129. Here we identify two hotspots, one formed by W90 and W113 on the FcγRIIIa hinge and another centered on Y132. W90 and W113 are conserved among human low affinity FcγRs and sandwich the IgG1 Fc P329 residue which is likewise conserved in IgG and IgE [11,41]. Previous studies suggest that this proline sandwich interaction is the primary binding interaction in FcγRs, which is consistent with results that mutation abolished binding. The importance of W90 and W113 is also supported by our functional data showing YTS cells expressing the FcγRIIIa W90A or W113A mutants do not exhibit measurable ADCC. Within this same region, I88A bound with 2-fold lower than V158. Although I88 was not detected in our amino acid selective NMR experiments, nearby V86 and L91 show large perturbations indicating conformational sampling of the interdomain interface, potentially reflecting domain flexibility. In the other hotspot, Y132 is one of many FcγRIIIa residues along the D and E beta strands that interacts with Fc [11]. We further probed this region testing Y132, H119, H134, K120, K131 and T122. The Y132S mutation eliminated binding, likely due to removing numerous stabilizing interactions. The IgG1 Fc D265 residue is critical and thought to stabilize the N297 glycan, in which mutation abolishes FcγRIIIa binding [42]. FcγRIIIa K120 is within distance to interact with D265, possibly playing an important role in Fc binding. We found the K120A mutation reduced binding 5-fold. Other mutations in this region revealed a comparatively minor impact compared to Y132, suggesting Y132 is the critical residue for binding one Fc domain. In addition, the FG loop plays a critical role in Fc binding. While mutation of residues L157 and S160 did not change affinity, K161A lowered affinity by 10-fold. The impact of the K161 mutation is interesting because K161 is not predicted to make direct contacts with Fc, although it may contribute to loop stabilization or may transiently contact the IgG1 Fc [11].

Conclusion

These results indicate FcγRIIIa engineering through substitutions aimed at stabilizing the Fc-bound conformation in the absence of ligand is expected to promote affinity and ADCC. Affinity gains are possible beyond that provided by the tighter-binding V158 allotype, and we demonstrate that relatively small affinity improvements have a substantial impact on ADCC. Finally, we revealed new structural insights into FcγRIIIa that may lead to NK cells engineered to bind antibody through FcγRIIIa with high affinity as a novel strategy to improve immunotherapies.

Materials and methods

Materials

All materials were purchased from Millipore-Sigma unless otherwise noted.

SPR

Affinity measurements were performed using the amine coupling strategy with a Biacore T200 (GE Life Sciences) as previously noted [19].

Protein expression

Plasmid construction, protein expression and purification were performed as previously described [19]. Briefly, all FcγRIIIa variants were cloned in the pGen2 vector with an 8x-histidine tag, green fluorescent protein (GFP) and tobacco etch virus (TEV) protease site. These constructs were transiently transfected into HEK293F (Life Technologies) or HEK293S (Gnt1-) cells [43] and harvested after 5 days. The collected media was spun down and passed over a Ni-NTA column (Qiagen) before being stored in 5 mM 3-(N-morpholino) propanesulfonic acid (MOPS), 0.1 M sodium chloride, pH 7.2 buffer.

Glycosidase Digestion

were purchased from NEB inc. 500 ug of FcγRIIIa-GFP was digested in 5 mM CaCl₂, 50 mM sodium acetate pH 5.5 buffer at a 100 uL volume. Digestions of α2-3,6,8 Neuraminidase, β1-4 Galactosidase S, and β-N-Acetylglucosaminidase S (NEB), or all three enzymes were performed overnight at 37 °C using 1 unit each of enzyme. Digestion was analyzed using SDS-PAGE and mass spectrometry. EndoF1 was expressed with *Escherichia coli* and exchanged into 20 mM sodium phosphate monobasic, 0.1 M KCl and 0.05 mM 4,4-dimethyl-4-silapentane-1-sulfonic acid in deuterium oxide. 2 uL of 7.5 mg/mL EndoF1 was added to 500 ug of FcγRIIIa in 40 uL and digested in the NMR tube for 2.5 hours at 4 °C.

Selective FcγRIIIa isotope labeling for NMR

FcγRIIIa-GFP was expressed in one of two labeling strategies, either 100 mg/L [¹⁵N]-lysine, [¹⁵N]-glycine and [¹⁵N]-serine or 100 mg/L [¹⁵N]-valine, [¹⁵N]-isoleucine and [¹⁵N]-leucine. These labels were supplemented in amino acid-free carbohydrate free FreeStyle293™ medium (Life Technologies) along with 1g/L glutamine, 100 mg/L of the other amino acids and 3 g/L glucose. pH then osmolarity were adjusted to 7.2 and 260-280 mOsm/kg respectively. The final media solutions were confirmed to be at pH 7.2 again before filtration through a sterile 0.2 μm aPES membrane (Fischer Scientific) and storage at 4 °C. Following expression in these media, the labeled FcγRIIIa-GFP was TEV protease digested and purified as described [19].

NMR Spectroscopy of FcγRIIIa N38Q/N74Q/N169Q

The expression plasmid encoding FcγRIIIa N38Q/N74Q/N169Q was generated from the plasmid encoding GFP-FcγRIIIa, using site directed mutagenesis [38]. HEK293F cells were transfected, and protein prepared for NMR as previously described [38,44]. Expression media for individual isotope [¹⁵N] labeling was prepared as previously described [25]. [¹³C, ¹⁵N]-FcγRIIIa N38Q/N74Q/N169Q was expressed in custom Freestyle amino acid and carbohydrate dropout medium (Invitrogen) containing 3 g/L [¹³C]-glucose and 100 mg/L of each [¹⁵N]-labeled amino acid, including: alanine, cysteine, aspartate, glutamate, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, arginine, serine, threonine, valine, tryptophan, and tyrosine. Unlabeled proline and glutamine were added a 100 mg/L and 2 g/L, respectively. FcγRIIIa was exchanged into NMR buffer containing 20 mM MOPS, 100 mM potassium chloride, 0.5 mM trimethylsilylpropanesulfonic acid (DSS) and 5% deuterium oxide at a final concentration of 100-300 μM.

NMR spectra were collected at a 30°C sample temperature using 700 and 800 MHz AVANCEIII spectrometers (Bruker) equipped with triple resonance cryoprobes. TROSY-based HSQC, HNCA, HNCOC and HNCO experiments were selected from the Bruker pulse sequence library. NMR data were processing in NMRPipe and analyzed using NMRView [45,46].

Lentivirus generation

Plasmids pMD2.G and psPAX2 were gifts from Didier Trono (Addgene plasmid # 12259; # 12260). Full length FcγRIIIa variant sequences were cloned under the CMV promoter in pCDH-CMV-MCS-EF1α-copGFP (System Biosciences). These three plasmids were cotransfected into HEK293T cells using Fugene 6 (Promega). Media was exchanged after three days and ultimately collected after five days total then passed through a 0.45μm syringe filter before being stored at -80C.

Transduction

1.5×10^6 YTS NK cells were cultured in 3 mL of media containing 1.8 mL of previously obtained viral media and 8μg/mL polybrene (Sigma). The culture plates were spun for 2 hours at 400 x g and then placed in an incubator overnight at 37 °C, 5% CO₂ and 80% humidity. The following day each well was transferred to 20 mL of fresh media and allowed to expand for another day. GFP signal was used to sort the cells on an S3 bulk sorter (Biorad), with transduction efficiencies as high as 30%.

Cell Culture

YTS cells (a gift from Dr.Mace, Columbia) and Raji cells (ATCC) were grown in RPMI 1640 medium supplemented with 10% FBS, l-glutamine (2 mM), HEPES (10 mM), sodium pyruvate (1 mM), non-essential amino acids (1 mM), and penicillin/streptomycin (50 U/mL) in suspension at 37°C, 5% CO₂. The ADCC assay was performed by flow cytometry performed as described previously [17].

Western blotting

1.28×10^7 YTS NK cells were collected and lysed in 100 μl of 1% SDS. Lysates were placed on ice for 1 minute and then sonicated for 10 seconds, repeated three times. Western blotting was performed as previously described [47]. Blots were stained with either for FcγRIIIa (AF1597; R&D) or GAPDH (NC1955142; R&D Systems). Both primary stainings were followed by anti-Goat secondary staining (A32860; Thermo-Fisher) before imaging on a LI-COR Odyssey CLx.

Molecular dynamics simulations

were performed as previously described using Amber and the Glycam forcefield [24]. Data were analyzed using VMD.

Statistical analyses

All statistical analyses were performed with Excel (Microsoft) and Prism 6.09 (GraphPad software).

Data availability statement

Backbone resonance assignments were deposited in the BioMagResBank as accession 52304. All other data generated or analyzed during this study are included in this published article (and its Supplementary Information files). Additional information is available to the corresponding author on reasonable request.

Acknowledgements

We thank Dr. Ganesh Subedi (Iowa State University) for preparing the [^{13}C , ^{15}N]-labeled receptor and collecting the triple-resonance-based NMR experiments and Dr. Ryan Weiss (UGA) for guidance with the lentiviral transduction procedure.

Additional information

Author Contributions

P.G.K and A.M.B. carried out experiments. P.G.K and A.W.B performed statistical analysis. A.W.B., is responsible for funding acquisition. A.W.B. and P.G.K designed the study and wrote the manuscript. All authors read and approved the final manuscript.

Funding

Funding to A.W.B. by the National Institutes of Health under Award No. U01 AI148114 (NIAID) and from the Biochemistry and Molecular Biology Department at the University of Georgia, Athens. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Competing interests

The authors declare no conflict of interest.

Supplemental figures and tables

FcγR3a Variant	Binding to fucosylated IgG1 Fc		Binding to afucosylated IgG1 Fc	
	K _D (nM)	StdDev (nM)	K _D (nM)	StdDev (nM)
EndoF F153S	35.07	22.98	44.40	38.18
EndoF R155S	105.77	13.44	86.27	3.57
EndoF S164A	111.73	54.12	118.80	41.30
EndoF S164A F153S	243.00	59.40	167.00	55.15
EndoF S164A V158F	381.50	62.93	320.00	72.12
EndoF S164A R155S	116.00	18.38	124.50	16.26
EndoF T167Y	261.00	151.32	225.50	95.46
EndoF V158	21.74	5.41	17.88	6.61
EndoF Y132S	12876.67	7035.73	7530.00	1547.87
F153S	322.75	144.04	133.95	44.51
V158F	944.75	228.50	238.75	58.96
G129D	>10000	n.a.	>10000	n.a.
H119A	477.00	100.80	225.67	78.78
H134A	771.67	251.14	339.67	80.03
I88A	360.33	269.47	227.77	239.49
K120A	1385.00	529.79	597.00	142.28
K128A	659.67	68.97	316.67	175.30
K128A R155S	n.b.	n.a.	n.b.	n.a.
K131A	549.00	223.76	330.60	211.95
K161A	2723.33	1201.68	1153.33	55.08
L124A	734.67	134.94	339.00	198.55
L157S	324.33	44.41	475.67	304.08
N162Q	200.00	103.58	118.30	44.83
R155S	637.67	117.59	619.00	435.44
S160A	326.00	142.04	131.53	59.71
S164A	159.13	76.79	92.19	67.71
S164A F153S	136.33	5.86	93.13	20.82
S164A V158F	1105.00	35.36	710.50	154.86
S164A I158	124.55	64.28	87.70	38.61
S164A K128A	252.50	58.69	189.00	84.85
S164A Man 3	108.53	42.75	15.43	3.88
S164A Man1	95.93	31.82	n.t.	n.a.
S164A N	131.98	34.70	n.t.	n.a.
S164A NG	112.45	50.15	n.t.	n.a.
S164A NGG	106.35	49.22	n.t.	n.a.
S164A R155S	128.30	88.67	94.25	71.77
S164A T171A	147.35	140.93	132.70	110.73
T122A	1197.67	462.08	640.33	221.41
T167Y	229.00	62.22	164.00	58.56
T171A	n.b.	n.a.	555.66	1031.54
V158	305.35	130.44	168.37	295.84
V158 Man 1	95.00	53.53	n.t.	n.a.
V158 Man3	27.50	14.65	15.63	3.42
V158 N	123.15	33.57	20.90	12.54
V158 NG	109.92	22.05	17.57	9.95
V158 NGG	87.78	24.99	13.71	7.19
V158I	210.27	98.28	101.77	67.45
W113A	n.b.	n.a.	>10000	n.a.
W90A	n.b.	n.a.	9040.00	1559.52
Y132S	n.b.	n.a.	>10000	n.a.

n.b.- no binding detected
n.a. - not applicable
n.t. - not tested

Supplemental Table 1.

Binding affinity measurements for each FcγRIIIa variant

Supplemental Table 2.

Raw ADCC data from the lentivirus transduced YTS cells.*


date	V158	V158	V158	V158	V158F	V158F	V158F	V158F	S164A	S164A	S164A	S164A	T167Y	T167Y	T167Y	T167Y
	RTX	aRTX	+K	+K	RTX	aRTX	+K	+K	RTX	aRTX	+K	+K	RTX	aRTX	+K	+K
12/6/23	9.2	14.8	9.4	14.2	0.9	11.7	1	16.1	10.5	8.4	6.2	-2	9.7	36.4	12.1	39.3
	9.7	13.8	11.6	15.2	1.9	11.3	1.3	11.1	9.5	4.4	6.6	4.9	5.4	46.7	15.8	54.8
	7	13.5	9.6	26.2	-0.6	22.7	2.4	30.9	7.7	8.3	9.7	13.8	7.3	66.5	20.5	63.8
12/13/23	3.3	35.2	25.2	42.9	1.9	18.6	3	25.4	21.2	25.1	17.8	25.1	9.4	9	10.5	40
	17.7	40.1	23.5	39.5	1.4	15.1	4.3	28.7	19.1	23.9	19.7	23.2	8.3	17.6	20.6	26.7
	17.7	38.6	24.4	43.1	-0.2	18.1	3.6	21.6	14.7	24.3	19.6	21.7	9.6	20.3	20.8	38.3
12/20/23	14.6	45.5	24.4	51.8	12.4	18.2	16.8	24.7	0.6	19.1	4.6	30.8	19.4	52.1	26.7	39
	13.8	47.5	30.1	54.2	10.6	31	19.5	28.1	2.9	34.4	4.8	36.2	24.1	53.1	24.6	36.84
	14.7	39	25.8	44.6	12.4	29.2	13.6	22.1	0.3	31	3.6	37.9	14.5	42.7	21.4	40.44
average	12	32	20	37	5	20	7	23	9.6	20	10.3	21	12	38	19	42

*V158= wt; aRTX = afucosylated rituximab, K=Kifunensine treatment

Supplemental Figure 1.

Comparison of expression and ADCC of the previously-established YTS-FcγRIIIa NK cell line and the lentivirus-transduced cell lines prepared herein.


A. Western blots showing expression levels compared to 40 ng of recombinant GFP-FcγRIIIa protein. “YTS-FcγRIIIa” refers to the previously established YTS-FcγRIIIa” cell line in contrast to the lenti-virus transduced YTS cells expressing various FcγRIIIa variants described herein. **B.** GAPDH expression levels of the YTS cells. **C.** The ADCC of the YTS-FcγRIIIa cell line is greater than our YTS cells transduced with FcγRIIIa V158. Data shown include three independent experiments collected on different days, each with three replicates.



Supplemental Figure 2.

Glycosidase digestions visualized by SDS-PAGE.


GFP-FcγRIIIa was treated with various glycosidases, revealing a stepwise increase in migration rate on a reducing SDS-PAGE gel. N= neuraminidase treated. NG=treatment with neuraminidase and galactosidase. NGG=treatment with neuraminidase, galactosidase and N-acetylglucosaminidase. Analyses of endoglycosidase F products are characterized elsewhere (Lampros et al. (2022) *Curr Res Immunol* 3:128-135).




Supplemental Figure 3.

Residue-specific labeling of the glycosylated FcγRIIIa.

A. FcγRIIIa with two N-glycans expressed from HEK293F cells grown in medium supplemented with [^{15}N]-Threonine. **B.** Peaks in the spectrum of [^{13}C , ^{15}N]-FcγRIIIa corresponding to threonine residues (*red* contours).





Supplemental Figure 6.

Backbone dihedral angles from two FcγRIIIa X-ray crystallography structures.

A. Phi-Psi angle plots for select residues in the FG loop. **B.** Table of Phi-Psi angles for select FcγRIIIa residues. 7seg and 5vu0 are pdb IDs for the two datasets analyzed.

References

1. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daeron M. (2009) **Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses** *Blood* **113**:3716–25
2. Hayes J.M., et al. (2017) **Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab** *Mol Cell Proteomics* **16**:1770–1788
3. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. (2002) **Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene** *Blood* **99**:754–8
4. Weng W.K., Levy R. (2003) **Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma** *J Clin Oncol* **21**:3940–7
5. Presta L.G., Shields R.L., Namenuk A.K., Hong K., Meng Y.G. (2002) **Engineering therapeutic antibodies for improved function** *Biochem Soc Trans* **30**:487–90
6. Mossner E., et al. (2010) **Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity** *Blood* **115**:4393–402
7. Townsend W., et al. (2023) **Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study** *Hemasphere* **7**
8. Patel K.R., Roberts J.T., Subedi G.P., Barb A.W. (2018) **Restricted processing of CD16a/Fc gamma receptor IIIa N-glycans from primary human NK cells impacts structure and function** *J Biol Chem* **293**:3477–3489
9. Subedi G.P., Barb A.W. (2018) **CD16a with oligomannose-type N-glycans is the only “low-affinity” Fc gamma receptor that binds the IgG crystallizable fragment with high affinity in vitro** *J Biol Chem* **293**:16842–16850
10. Moremen K.W., Tiemeyer M., Nairn A.V. (2012) **Vertebrate protein glycosylation: diversity, synthesis and function** *Nat Rev Mol Cell Biol* **13**:448–62
11. Sondermann P., Huber R., Oosthuizen V., Jacob U. (2000) **The 3.2-Å crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex** *Nature* **406**:267–73
12. Patel K.R., Nott J.D., Barb A.W. (2019) **Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability** *Mol Cell Proteomics* **18**:2178–2190
13. Roberts J.T., Patel K.R., Barb A.W. (2020) **Site-specific N-glycan Analysis of Antibody-binding Fc gamma Receptors from Primary Human Monocytes** *Mol Cell Proteomics* **19**:362–374
14. Patel K.R., Roberts J.T., Barb A.W. (2020) **Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes** *Glycobiology* **30**:427–432

15. Patel K.R., Rodriguez Benavente M.C., Lorenz W.W., Mace E.M., Barb A.W. (2021) **Fc gamma receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells** *J Biol Chem* **296**
16. Benavente M.C.R., Hakeem Z.A., Davis A.R., Murray N.B., Azadi P., Mace E.M., Barb A.W. (2024) **Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC** *Sci Rep* **14**
17. Rodriguez Benavente M.C., Hughes H.B., Kremer P.G., Subedi G.P., Barb A.W. (2023) **Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells** *Immunology* **170**:202–213
18. Vidarsson G., Dekkers G., Rispens T. (2014) **IgG subclasses and allotypes: from structure to effector functions** *Front Immunol* **5**
19. Kremer P.G., Barb A.W. (2022) **The weaker-binding Fc gamma receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface** *J Biol Chem* **298**
20. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., Presta L.G. (2002) **Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity** *J Biol Chem* **277**:26733–40
21. Ferrara C., et al. (2011) **Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc gamma RIII and antibodies lacking core fucose** *Proc Natl Acad Sci U S A* **108**:12669–74
22. Mizushima T., Yagi H., Takemoto E., Shibata-Koyama M., Isoda Y., Iida S., Masuda K., Satoh M., Kato K. (2011) **Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans** *Genes Cells* **16**:1071–80
23. Sakae Y., Satoh T., Yagi H., Yanaka S., Yamaguchi T., Isoda Y., Iida S., Okamoto Y., Kato K. (2017) **Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fc gamma receptor IIIa** *Sci Rep* **7**
24. Falconer D.J., Subedi G.P., Marcella A.M., Barb A.W. (2018) **Antibody Fucosylation Lowers the Fc gamma RIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan** *ACS Chem Biol* **13**:2179–2189
25. Subedi G.P., Roberts E.T., Davis A.R., Kremer P.G., Amster I.J., Barb A.W. (2024) **A comprehensive assessment of selective amino acid (15)N-labeling in human embryonic kidney 293 cells for NMR spectroscopy** *J Biomol NMR*
26. Wyss D.F., Choi J.S., Wagner G. (1995) **Composition and sequence specific resonance assignments of the heterogeneous N-linked glycan in the 13.6 kDa adhesion domain of human CD2 as determined by NMR on the intact glycoprotein** *Biochemistry* **34**:1622–34
27. Yagi H., Zhang Y., Yagi-Utsumi M., Yamaguchi T., Iida S., Yamaguchi Y., Kato K. (2015) **Backbone (1)H, (13)C, and (15)N resonance assignments of the Fc fragment of human immunoglobulin G glycoprotein** *Biomol NMR Assign* **9**:257–60
28. Yogo R., Yanaka S., Kato K. (2018) **Backbone (1)H, (13)C, and (15)N assignments of the extracellular region of human Fc gamma receptor IIIb** *Biomol NMR Assign* **12**:201–204

29. Roberts J.T., Barb A.W. (2018) **A single amino acid distorts the Fc gamma receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a** *J Biol Chem* **293**:19899–19908
30. Kakiuchi-Kiyota S., et al. (2022) **A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma** *Leukemia* **36**:1006–1014
31. Van Coillie J., et al. (2022) **Role of N-Glycosylation in FcgammaRIIIa interaction with IgG** *Front Immunol* **13**
32. Tolbert W.D., et al. (2022) **Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques** *Front Immunol* **13**
33. Page A., Chuvain N., Valladeau-Guilemond J., Depil S. (2024) **Development of NK cell-based cancer immunotherapies through receptor engineering** *Cell Mol Immunol* **21**:315–331
34. Larsen M.D., et al. (2021) **Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity** *Science* **371**
35. Kapur R., et al. (2014) **A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy** *Blood* **123**:471–80
36. Ackerman M.E., et al. (2013) **Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity** *J Clin Invest* **123**:2183–92
37. Hatjiharissi E., et al. (2007) **Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcgammaRIIIa-158 V/V and V/F polymorphism** *Blood* **110**:2561–4
38. Subedi G.P., Hanson Q.M., Barb A.W. (2014) **Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcgammaRIIIa binding** *Structure* **22**:1478–88
39. Subedi G.P., Barb A.W. (2015) **The Structural Role of Antibody N-Glycosylation in Receptor Interactions** *Structure* **23**:1573–1583
40. Imberty A., Perez S., Hricovini M., Shah R.N., Carver J.P. (1993) **Flexibility in a tetrasaccharide fragment from the high mannose type of N-linked oligosaccharides** *Int J Biol Macromol* **15**:17–23
41. Tamm A., Schmidt R.E. (1997) **IgG binding sites on human Fc gamma receptors** *Int Rev Immunol* **16**:57–85
42. Baudino L., et al. (2008) **Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions** *J Immunol* **181**:6664–9
43. Reeves P.J., Callewaert N., Contreras R., Khorana H.G. (2002) **Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line** *Proc Natl Acad Sci U S A* **99**:13419–24

44. Subedi G.P., Falconer D.J., Barb A.W. (2017) **Carbohydrate-Polypeptide Contacts in the Antibody Receptor CD16A Identified through Solution NMR Spectroscopy** *Biochemistry* **56**:3174–3177
45. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. (1995) **NMRPipe: a multidimensional spectral processing system based on UNIX pipes** *J Biomol NMR* **6**:277–93
46. Johnson B.A (2004) **Using NMRView to visualize and analyze the NMR spectra of macromolecules** *Methods Mol Biol* **278**:313–52
47. Shenoy A., Yalamanchili S., Davis A.R., Barb A.W. (2021) **Expression and Display of Glycoengineered Antibodies and Antibody Fragments with an Engineered Yeast Strain** *Antibodies (Basel)* **10**

Editors

Reviewing Editor

Julien Roche

Iowa State University, Ames, United States of America

Senior Editor

Amy Andreotti

Iowa State University, Ames, United States of America

Reviewer #1 (Public review):

Summary:

In this work, the authors continue their investigations on the key role of glycosylation to modulate the function of a therapeutic antibody. As follow up of their previous demonstration on how ADCC was heavily affected by the glycans at the Fc gamma receptor (FcγR)IIIa, they now dissect the contributions of the different glycans that decorate the diverse glycosylation sites. Using a well designed mutation strategy, accompanied by exhaustive biophysical measurements, with extensive use of NMR, using both standard and newly developed methodologies, they demonstrate that there is one specific locus, N162, which is heavily involved in the stabilization of (FcγR)IIIa and that the concomitant NK function is regulated by the glycan at this site.

Strengths:

The methodological aspects are carried out at the maximum level.

Weaknesses:

The exact (or the best possible assessment) of the glycan composition at the N162 site.

<https://doi.org/10.7554/eLife.100083.2.sa2>

Reviewer #2 (Public review):

Summary:

The authors set out to demonstrate a mechanistic link between Fcγ receptor (IIIa) glycosylation and IgG binding affinity and signaling - resulting in antibody-dependent cellular cytotoxicity - ADCC. The work builds off prior findings from this group about the general impact of glycosylation on FcR (Fc receptor)-IgG binding.

Strengths:

The structural data (NMR) is highly compelling and very significant to the field. A demonstration of how IgG interacts with FcγRIIIa in a manner sensitive to glycosylation of both the IgG and the FcR fills a critical knowledge gap. The approach to demonstrate the selective impact of glycosylation at N162 is also excellent and convincing. The manuscript/study is, overall, very strong.

Weaknesses:

After revision, which I feel addressed the minor concerns well, the last comment about significance in the long-term is all that remains. Essentially, it will be important in downstream research to determine whether changes in N162 glycan composition ever occur naturally as a result of some factor(s) that include various disease states, inflammation, age, and so on. The answer (either way) does not diminish the importance of understanding molecular details governing antibody-receptor interactions, but it would be very interesting to know if those glycans are regulated in a way that modulates ADCC activity.

<https://doi.org/10.7554/eLife.100083.2.sa1>

Author response:

The following is the authors' response to the original reviews.

Public Reviews:

Reviewer #1 (Public Review):

Summary:

In this work, the authors continue their investigations on the key role of glycosylation to modulate the function of a therapeutic antibody. As a follow-up to their previous demonstration on how ADCC was heavily affected by the glycans at the Fc gamma receptor (FcγR)IIIa, they now dissect the contributions of the different glycans that decorate the diverse glycosylation sites. Using a well-designed mutation strategy, accompanied by exhaustive biophysical measurements, with extensive use of NMR, using both standard and newly developed methodologies, they demonstrate that there is one specific locus, N162, which is heavily involved in the stabilization of (FcγR)IIIa and that the concomitant NK function is regulated by the glycan at this site.

Strengths:

The methodological aspects are carried out at the maximum level.

Weaknesses:

The exact (or the best possible assessment) of the glycan composition at the N162 site is not defined.

We revised the Introduction to include previous findings from our laboratory regarding processing on YTS cells:

“YTS cells, a key cytotoxic human NK cell line used for these studies, express FcγRIIIa with extensive glycan processing, including the N162 site with predominantly hybrid and complex-type glycoforms {Patel 2021}.”

Reviewer #2 (Public Review):

Summary:

The authors set out to demonstrate a mechanistic link between Fcγ receptor (IIIa) glycosylation and IgG binding affinity and signaling - resulting in antibody-dependent cellular cytotoxicity - ADCC. The work builds off prior findings from this group about the general impact of glycosylation on FcR (Fc receptor)-IgG binding.

Strengths:

The structural data (NMR) is highly compelling and very significant to the field. A demonstration of how IgG interacts with FcγRIIIa in a manner sensitive to glycosylation of both the IgG and the FcR fills a critical knowledge gap. The approach to demonstrate the selective impact of glycosylation at N162 is also excellent and convincing. The manuscript/study is, overall, very strong.

Weaknesses:

There are a number of minor weaknesses that should be addressed.

(1) Since S164A is the only mutant in Figure 1 that seems to improve affinity, even if minimally, it would be a nice reference to highlight that residue in the structural model in panel B.

We revised Figure 1B to include the S164 site.

(2) It is confusing why some of the mutants in the study are not represented in Figure 1 panel A. Those affinities and mutants should be incorporated into panel A so the reader can easily see where they all fall on the scale.

We thank the reviewer for this comment. We restructured the Results section to highlight that a primary outcome of the experiment referenced was to map the contribution of interface residues to antibody binding affinity. These data were not previously available, highlighting hotspots at the interface. Figure 1A and B report these results.

We then used a subset of mutations from this experiment, as well as a subset of mutations from an additional library containing mutations proximal to the interface, to build a small library for evaluation using ADCC. The complete binding data for all variants, binding to two different IgG1 Fc glycoforms, is presented in Supplemental Table 1.

T167Y in particular needs to be shown, as it is one of few mutants that fall between what seems to be ADCC+ and ADCC- lines. Also, that mutant seems to have a stronger affinity compared to wt (judged by panel D), yet less ADCC than wt. This would imply that the relationship between affinity and activity is not as clean as stated, though it is clearly important. Comments about this would strengthen the overall manuscript.

We thank the reviewer for this particular insight. We agree that the lack of a clean correlation between ADCC potency and affinity implies additional factors that could have affected these experimental results. We added the following sentence to the discussion.

“Notably, the ADCC potency for those high-affinity variants does not fall cleanly on a line, indicating that other factors affect our observations, which may include organization at the cell surface, changes to glycan composition, or receptor trafficking.”

(3) This statement feels out of place: "In summary, this result demonstrates that the sensitivity to antibody fucosylation may be eliminated through FcγRIIIa engineering while preserving antibody-binding affinity." In Figure 2, the authors do indeed show that mutations in FcγRIIIa can alter the impact of IgG core fucosylation, but implying that receptor engineering is somehow translatable or as impactful therapeutically as engineering the antibody itself deflates the real basic science/biochemical impact of understanding these interactions in molecular detail. Not everything has to be immediately translatable to be important.

We agree and removed the highlighted sentence.

(4) The findings reported in Figure 2, panel C are exciting. Controls for the quality of digestion at each step should be shown (perhaps in supplementary data).

We agree. We added an example of the digestions as Figure S2.

(5) Figure 3 is confusing (misabeled?) and does not show what is described in the Results. First, there is a F158V variant in the graph but a V158F variant in the text.

Please correct this.

Thank you for identifying this typo. We corrected Figure 3.

Second, this variant (V158F/F158V) does not show the 2-fold increase in ADCC with kifunensine as stated.

Thank you for drawing our attention to this rounding error. We revised the text to report a statistically significant 1.4-fold increase.

Finally, there are no statistical evaluations between the groups (+/- kif; +/- fucose).

We provide the p values for +/-fuc and +/- Kifunensine for each YTS cell line in the figure. We did not provide a global comparison of p values that included all cell lines due to some cell lines experiencing a significant change and others not. However, we added the raw data as Supplemental Table 2 should readers wish to perform these analyses.

The differences stated are not clearly statistically significant given the wide spread of the data. This is true even for the wt variant.

We agree that there are points that overlap in this figure between the different treatments. However, our use of the students T-test (two tailed) using three experiments collected on three different days (each with three technical replicates) provides enough resolution to determine the significance of difference of the means for the different treatments. This is, by our estimation, a highly rigorous manner to collect and analyze the data.

(6) The kifunensine impact is somewhat confusing. They report a major change in ADCC, yet similar large changes with trimming only occur once most of the glycan is nearly gone (Figure 2). Kifunensine will tend to generate high mannose and possibly a few hybrid glycans. It is difficult to understand what glycoforms are truly important outside of stating that multi-branched complex-type N-glycans decrease affinity.

Note that Figure 2 does not evaluate the kifunensine-treated glycan, which is mostly Man8 and Man9 structures. In our previous work, these structures likewise provide increased binding affinity (see pubmed ID 30016589). We believe the most important message is that composition of the N162 glycan (removed with the S164A mutation) regulates NK cell ADCC. On cells, we are not able to modulate N162 glycan composition without affecting potentially every other N-glycan on the surface, so we do not have an ADCC experiments that is directly comparable to Figure 2. Thus, this increased ADCC resulting from kifunensine treatment is consistent with previously observed increases in binding affinity measurement.

(7) This is outside of the immediate scope, but I feel that the impact would be increased if differences in NK cell (and thus FcγRIIIA) glycosylation are known to occur during disease, inflammation, age, or some other factor - and then to demonstrate those specific changes impact ADCC activity via this mechanism.

We agree completely. As mentioned in the Introduction, we know that N162 glycan composition varies substantially from donor to donor based on previous work from our lab. Curiously, little variability appeared between donors at the other four Nglycosylation sites. Thus, there is the potential that different NK cell N162 glycan compositions are coincident with different indications. This is an area we are quite interested in pursuing.

<https://doi.org/10.7554/eLife.100083.2.sa0>